A5060125444- Opioid Use Disorder Treatment
- Substance Abuse Treatment and Outcomes
- Pain Management and Opioid Use
- HIV, Drug Use, Sexual Risk
- Musculoskeletal pain and rehabilitation
- Prenatal Substance Exposure Effects
- Mental Health and Patient Involvement
- Pharmaceutical Practices and Patient Outcomes
- Health Policy Implementation Science
- Digital Mental Health Interventions
- Mental Health Treatment and Access
- Forensic Toxicology and Drug Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Pain Mechanisms and Treatments
- Treatment of Major Depression
- Poisoning and overdose treatments
- Homelessness and Social Issues
- Cannabis and Cannabinoid Research
- Hormonal and reproductive studies
- Telemedicine and Telehealth Implementation
- Eating Disorders and Behaviors
- Pain Management and Placebo Effect
- Schizophrenia research and treatment
- Mobile Health and mHealth Applications
- Healthcare Policy and Management
University of Wollongong
2018-2025
UNSW Sydney
2014-2024
Illawarra Health and Medical Research Institute
2019-2024
National Centre for Clinical Research on Emerging Drugs
2015-2018
The University of Sydney
2014-2018
Pearson (United States)
2018
Children's Hospital at Westmead
2018
University of Connecticut
2017
Durham University
2017
Medical University of Vienna
2017
BackgroundInterest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because their potential reduce opioid dose requirements. We aimed investigate people living with who had been prescribed opioids, including reasons for perceived effectiveness cannabis; associations between amount pain, mental health, use; effect on severity interference over time; opioid-sparing effects cannabis.MethodsThe Pain Opioids IN Treatment study a prospective, national,...
To document trends in: (i) prescribing of morphine and oxycodone; (ii) hospital separations for overdose; (iii) presentations treatment problems associated with these drugs; (iv) oxycodone-related mortality data in Australia.Cross-sectional study analysing prescriptions oxycodone based on figures adjusted using Australian Bureau Statistics estimated resident population prospectively collected from: the National Hospital Morbidity Database primarily attributed to poisoning opioids other than...
ObjectiveBenzodiazepines (BZDs) are commonly used by chronic pain patients, despite limited evidence of any long-term benefits and concerns regarding adverse events drug interactions, particularly in older patients. This article aims to: describe patterns BZDs use; the demographic, physical, mental health correlates BZD examine if negative outcomes associated with use after controlling for confounders.
There has been a recent increase in public and professional concern about the prescription of strong opioids for pain. Despite this concern, research to date limited because number factors such as small sample sizes, exclusion people with complex comorbidities, studies short duration. The Pain Opioids IN Treatment is 2-year prospective cohort study 1500 prescribed pharmaceutical their chronic This article provides an overview demographic clinical characteristics using baseline data 1514...
There is increasing concern about the appropriateness of prescribing pharmaceutical opioids for chronic non-cancer pain (CNCP), given risks problematic use and dependence. This article examines opioid dose dependence correlates each.Baseline data were obtained from a national sample 1,424 people across Australia (median 58 years, 55% female experiencing median 10 years), who had been prescribed CNCP. Current consumption was estimated in oral morphine equivalent (OME; mg per day), ICD-10...
Abstract Purpose There has been concern regarding the increasing use of opioids and related harm. We present data on opioid utilisation across Australia consider sociodemographic factors that may affect rates. Methods IMS Health national sales for over‐the‐counter (codeine) prescription (buprenorphine, codeine, dextropropoxyphene, fentanyl, hydromorphone, methadone, morphine, oxycodone, tapentadol tramadol) were used to estimate total rates in community during 2013, mapped Statistical Local...
To examine characteristics of first-time methadone and buprenorphine clients factors associated with risk leaving first treatment in New South Wales (NSW), Australia. Retrospective linkage study opioid substitution therapy (OST) treatment, court, custody mortality data. NSW, First-time OST entrants (August 2001-December 2010). Characteristics were examined. Time-dependent Cox models examined the demographic, criminographic variables jointly considered. Interactions between medication other...
Abstract Aims To examine perceptions of extended‐release (XR) buprenorphine injections among people who regularly use opioids in Australia. Design Cross‐sectional survey prior to implementation. XR‐buprenorphine was registered Australia November 2018. Setting Sydney, Melbourne and Hobart. Participants A total 402 interviewed December 2017 March Measurements Primary outcome concerned the proportion participants believed would be a good treatment option for them, preferred weekly versus...
Performance- and image-enhancing drugs have the potential to be a significant public health issue. Detailed data on PIEDs injection are difficult obtain because of illicit unsupervised way in which many used, hidden nature group. Our study examines patterns use, risk behaviours related harm associated with injection. We also report ways users currently seek injecting equipment harm-reduction advice.Data were obtained via structured questionnaire administered face-to-face interviews 60 men...
Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription dependence, and is long-term maintenance of treatment compared taper or psychological alone?For patients who are dependent on opioids, agonists less use better adherence to medication therapies dependence alone. Methadone was not therapeutic buprenorphine treatment. Evidence quality low moderate.
To assess how well the defined daily dose (DDD) metric reflects opioid utilisation among chronic non-cancer pain patients.Descriptive, cross-sectional study, utilising a 7-day medication diary.Community-based treatment settings, Australia.A sample of 1101 people prescribed opioids for pain.Opioid data was collected via self-completed diary capturing names, strengths and doses each taken in past week. Median calculated opioid. Comparisons were made to World Health Organization's (WHO) DDD...
Abstract The International Classification of Diseases (ICD) and the Diagnostic Statistical Manual (DSM) are routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids they remain controversial. In pain medicine, concept “Addiction” is preferred with reduced emphasis on tolerance withdrawal. This article examines prevalence characteristics pharmaceutical opioid dependence/disorder according to ICD, DSM, medicine “Addiction,” among chronic noncancer...
Opioid agonist treatment (OAT) is an effective intervention for opioid dependence. Extended-release buprenorphine injections (BUP-XR) may have additional potential benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community healthcare settings Australia, permitting examination when delivered standard practice.Participants were recruited from a network specialist public drug services, primary care and some...
Internationally, there is concern about the increased prescribing of pharmaceutical opioids for chronic non-cancer pain (CNCP). In part, this related to limited knowledge long-term benefits and outcomes opioid use CNCP. There has also been injection some by people who inject drugs, patients, development problematic and/or dependent use. To date, much research on among with CNCP, have clinical trials that excluded patients complex needs, duration (i.e. fewer than 12 weeks). The Pain Opioids...
Abstract Introduction and Aims Emerging research suggests that the sub‐population of anabolic–androgenic steroid (AAS) users who experience physical appearance concerns may suffer greater psychological dysfunction than other sub‐populations, including with athletic or occupational concerns. Thus, among current AAS users, we sought to determine whether, what extent, social physique anxiety—an established measure concern—was associated dysfunction. Design Methods Interviews were conducted a...
Abstract Purpose Although pharmaceutical claims are an essential data source for pharmacoepidemiological studies, these potentially under‐estimate opioid utilisation. Therefore, this study aimed to quantify the extent which from Australia's national medicines subsidy programs (Pharmaceutical Benefits Scheme [PBS] and Repatriation Schedule of Pharmaceutical [RPBS]) prescription‐only total utilisation across time different opioids. A secondary aim was examine impact 2012 policy change record...